Impact of NRAS Mutations on the Diagnosis of Follicular Neoplasm of the Thyroid

Table 2

Clinicopathologic features and the NRAS mutation status of 60 thyroid cancers with a preoperative diagnosis of follicular neoplasm.

	Patients with a NRAS negative thyroid cancer	Patients with a NRAS positive thyroid cancer	-value
Average tumor size (cm)	2.2 ± 1.4	1.4 ± 0.9	0.012
Age
45 years	17 (59%)	12 (41%)	0.464
>45 years	21 (68%)	10 (32%)
Gender
Female	26 (62%)	16 (38%)	0.726
Male	12 (67%)	6 (33%)
Histopathology
Encapsulated FVPTC	19 (51%)	18 (49%)
Infiltrative FVPTC	4 (67%)	2 (33%)
Classic PTC	3 (100%)	0
FTC	11 (85%)	2 (15%)
Poorly differentiated	1 (100%)	0
Capsular invasion
Negative	13 (50%)	13 (50%)	0.061
Positive	25 (74%)	9 (26%)
Vascular invasion
Negative	31 (61%)	20 (39%)	0.329
Positive	7 (78%)	2 (22%)
Lymph node metastasis
Negative	25 (66%)	13 (34%)	0.400
Positive	4 (50%)	4 (50%)

FVPTC, follicular variant of papillary thyroid carcinoma; PTC, papillary thyroid carcinoma; FTC, follicular thyroid carcinoma.